An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seres Therapeutics, Inc. (MCRB) will host a conference call to discuss Q4 and full year 2023 results and provide a business update on March 5, 2024. Investors can access the call via phone or webcast.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4030622. To join the live webcast, please visit the “Investor and News” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. For more information, please visit www.serestherapeutics.com.
When will Seres Therapeutics host a conference call to discuss Q4 and full year 2023 results?
Seres Therapeutics will host a conference call on March 5, 2024.
What is the ticker symbol for Seres Therapeutics?
The ticker symbol for Seres Therapeutics is MCRB.
How can investors access the conference call?
Investors can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) and referencing the conference ID number 4030622.
Where can investors find the webcast replay?
Investors can find the webcast replay on the Seres website in the 'Investor and News' section, available approximately two hours after the event and archived for about 21 days.
